List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Globoid Cell Leukodystrophy (Krabbe Disease) - Overview
Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development
Commence Bio Inc
Kyorin Pharmaceutical Co Ltd
Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profiles
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RND-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Globoid Cell Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects
Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products
Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones
Featured News & Press Releases
Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease
Jun 03, 2015: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Commence Bio Inc, H1 2018
Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, H1 2018
Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned
• Commence Bio Inc
• Kyorin Pharmaceutical Co Ltd